Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Cardiovascular
Immunology
Neuroscience
Oncology
iptacopan - CFB inhibitor
NCT04889430 APPELHUS (CLNP023F12301)
Indication
Phase
Atypical haemolytic uraemic syndrome
Phase 3
Patients
50
Primary
Outcome
Percentage of participants with complete TMA response without the use of
PE/PI and anti-C5 antibody
Measures
Arms
Intervention
Target
Patients
Single arm open-label with 50 adult patients receiving 200mg oral twice daily
doses of iptacopan
Adult patients with aHUS who are treatment naive to complement inhibitor
therapy (including anti-C5 antibody)
Read-out
Milestone(s)
2024
Publication
TBD
References
Abbreviations
Other
67 Investor Relations | Q3 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation